Disease-free survival as surrogate for overall survival in real-world settings for esophageal cancer: an analysis of SEER-Medicare data.

ABSTRACT:

Background

Establishing surrogate endpoints for overall survival (OS) may expedite assessment of new therapies in esophageal cancer (EC) and gastroesophageal junction cancer (GEJC). This study aimed to evaluate disease-free survival (DFS) as a surrogate endpoint for OS.

Methods

Patients from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database aged ≥66 years with resection after primary diagnosis of stage 2 or 3 EC/GEJC between 2009 and 2017 were analyzed (N = 925; median follow-up 26.2 months). Surrogacy was assessed by evaluating individual level associations between DFS and OS using Spearman's rank correlation and the association between treatment effects by Pearson's correlation coefficient. To evaluate the association between treatment effects, patie

SUBMITTER: Ajani JA 

PROVIDER: S-EPMC11574803 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature